Samjin Pharmaceutical Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, inflammatory bowel disease, arthritis and migraine.
Intelligen Therapeutics Co. Ltd. and Intelligen Therapeutics Inc. have disclosed macrocyclic compounds acting as TNF-α inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases.
The TCF4/β-catenin axis is a key driver of tumor growth, where β-catenin has remained resistant to therapy and is traditionally considered an undruggable protein. At the ACS Fall 2025 meeting, Parabilis Medicines Inc. divulged results of work on hyperstabilized α-helical peptides named helicons that directly bind to β-catenin and block its interaction with TCF transcription factors such as TCF4, as well as inhibit the Wnt signaling pathway.
The WEE1 tyrosine kinase is an important cell cycle regulator that inhibits cell cycle progression during the S and G2/M phases to impede the division of cells with DNA damage. Tumor cells with replicative stress are thought to rely on WEE1 for their survival.
Researchers at Zhengzhou University and two of its affiliated hospitals explored in a mouse model whether brozopine might mitigate ischemia-induced vascular dementia.
Effective vaccines against Staphylococcus aureus remain out of reach: 10 candidates that showed promise in preclinical animal models have failed in clinical trials. Researchers at Third Military Medical University and collaborators reasoned that one of the reasons might be that 70%-80% of the population has developed antibodies to the pathogen.
Medipal Holdings Corp. and JCR Pharmaceuticals Co. Ltd. have signed an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479, an investigational therapy for the lysosomal storage disorder GM2 gangliosidosis.
Researchers at Seoul National University and the National Cancer Center examined public datasets from patients as well as the whole-exome sequence from one of their own patients, who developed radiation-induced sarcoma after treatment.
Guangzhou Fermion Technology Co. Ltd. has described non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of allergy, autoimmune disease, cancer, dermatological disorders, dry eye, myelofibrosis, neurological disorders and transplant rejection, among others.
Luye Innomind Pharma Shijiazhuang Co. Ltd. has divulged salts of 5-HT2A receptor inverse agonists with improved stability reported to be useful for the treatment of bipolar disorder, depression, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, sleep disorders, anxiety disorders and schizophrenia.
RSS
